Healthspan vs Lifespan: What Longevity Research Actually Measures

This content is educational. It describes how longevity research defines and measures the metrics it studies. It is not medical advice.

Why the distinction matters

"Longevity" is one of the most-used and least-defined words in consumer health. Brands, influencers, and clinics use it to mean almost anything — sometimes a vague aspiration toward better long-term health, sometimes a specific claim about extending life, sometimes a marketing wrapper around interventions whose actual research base concerns something quite different.

Researchers use two specific terms: lifespan and healthspan. They mean different things, are measured differently, and represent different goals. Most consumer-facing longevity content conflates them. Understanding the distinction is the difference between reading the field clearly and being a target for it.

This page describes the definitions, how researchers measure each metric, how they have diverged in recent decades, and what current research is actually trying to extend.

The definitions

Lifespan is the length of life from birth to death. It is measured in years. It is the metric used by demographers, insurance actuaries, and life-expectancy statistics.

Healthspan is the length of life spent in good health — free from major disease, disability, or significant functional impairment. It is shorter than lifespan by definition: every life that ends in death includes some period of declining health before the end. The question is how long that period is and how severe.

A simple way to picture the distinction: lifespan is the total length of the line; healthspan is the length of the line that is unbroken by major illness.

The terms are not interchangeable. Extending lifespan without extending healthspan means prolonging the period of poor health. Extending healthspan without extending lifespan means compressing morbidity into a shorter end-of-life period — sometimes called "compression of morbidity," a goal first articulated by James Fries in 1980.

How lifespan is measured

Lifespan is the easier of the two to measure. Death is a defined event, recorded by national statistics offices, and aggregated into life expectancy figures.

The most-cited lifespan metric is life expectancy at birth — the average number of years a newborn would live if current mortality rates persisted across their lifetime. The WHO and national statistics offices publish this figure annually.

Key features of lifespan as a metric:

• Unambiguous endpoint (death)
• Reliably measured across populations
• Allows historical comparison (we have reasonable data going back centuries in some countries)
• Conflates "how long people live" with "how the population is structured" — but standard demographic adjustments handle this

Globally, life expectancy at birth was approximately 73 years in 2024 [WHO]. In high-income countries it ranged from approximately 80 to 85 years. In lower-income countries it ranged from approximately 60 to 70 years.

How healthspan is measured

Healthspan is much harder to measure because "good health" doesn't have a single defining endpoint. Researchers use several proxies:

Healthy Life Expectancy (HALE)

HALE is the WHO's principal healthspan metric. It is calculated as the average number of years a person can expect to live in "full health" — defined as life lived without the burden of measured diseases and injuries. HALE adjusts for the severity of health states using disability weights derived from population surveys.

For 2019 (the most recent comprehensive WHO HALE figures), the global HALE at birth was approximately 63 years, against a global life expectancy of approximately 73 years. The gap — roughly 10 years — is the period people on average spend in less-than-full health before death.

Disability-Free Life Expectancy (DFLE)

DFLE measures the years of life expected to be lived without specific defined disabilities, typically activities of daily living (ADL) limitations or instrumental activities of daily living (IADL) limitations. The European Health and Life Expectancy Information System (EHLEIS) publishes DFLE comparisons across European member states.

Disease-Free Life Expectancy

Years lived without major chronic conditions (cardiovascular disease, cancer, diabetes, dementia). This metric is the most clinically intuitive but is sensitive to how diseases are defined and detected — earlier diagnosis can paradoxically shorten apparent "disease-free" years.

Years Lived with Disability (YLDs)

Used in Global Burden of Disease analyses. Each year of life is weighted by the severity of conditions experienced. Aggregate YLDs across a population give a sense of total morbidity burden.

Composite indices

Some researchers propose composite indices combining mortality, morbidity, frailty, and cognitive function. None has reached the consensus status of HALE.

How lifespan and healthspan have diverged

In high-income countries, lifespan has increased significantly over the past century — gains of roughly 25-30 years in many developed nations since 1900. The question of whether healthspan has kept pace is empirically contested.

The data suggests two patterns:

1. Healthspan has grown, but more slowly than lifespan in some populations. WHO HALE figures show that the gap between life expectancy and healthy life expectancy has been roughly stable or slowly widening in many developed countries. People live longer; they also spend more total years in poor health.

2. The gap varies across populations. Some countries with the highest life expectancies (Japan, Italy, Spain) maintain relatively compressed end-of-life morbidity periods. Others (US, UK in recent years) show longer periods of multimorbidity at older ages.

The Global Burden of Disease 2019 update by the Institute for Health Metrics and Evaluation reported that globally, gains in healthy life expectancy from 2000 to 2019 were smaller than gains in total life expectancy — meaning the average person in 2019 lived longer than the average person in 2000 but also spent more years in compromised health.

This pattern is the central concern of healthspan research. Extending the life of the line is the easier problem; keeping more of the line unbroken is the harder one.

What current longevity research is trying to extend

The longevity research field is split, sometimes uncomfortably, into research orientations with different goals:

Geroscience. A research program focused on the biology of ageing itself — the cellular and molecular processes that drive multiple age-related diseases simultaneously. The geroscience hypothesis is that interventions targeting these processes could extend healthspan by delaying multiple diseases at once. Major research programs in mTOR inhibition, senolytics, NAD+ metabolism, cellular reprogramming, and metabolic pathways sit here.

Compression of morbidity. Research focused explicitly on compressing the late-life decline into a shorter, sharper window. Public health, exercise science, and chronic disease prevention research broadly fall here.

Life extension. Research focused on extending maximum lifespan — typically focused on the biological limits to life. This is the most speculative and most-debated end of the field.

These orientations overlap. An intervention that delays cardiovascular disease can extend both lifespan and healthspan. An intervention that targets cellular senescence might do the same. But the goals differ, and the consumer-facing communication about each is often imprecise.

Researchers in the field have explicitly argued for healthspan as the primary goal. The 2018 Nature Reviews Drug Discovery commentary by Bellantuono and others argued that "extending healthspan, not lifespan, should be the primary goal of geroscience research." The consumer marketing of longevity products has not consistently followed.

Common misuses in popular content

Several patterns recur in consumer longevity content that distort what the research describes:

Conflation of the two metrics. "X extends longevity" usually means "X has some association with lifespan or healthspan in a specific population." It rarely means "X has been shown to extend healthy life expectancy in a generalisable trial."

Animal-to-human leaps. Many touted longevity interventions have evidence in mice, flies, or worms — short-lived species whose biology of ageing differs from humans. Translation to human healthspan or lifespan benefit is not automatic.

Surrogate biomarker substitution. "Reduces a biomarker associated with ageing" is not the same as "extends healthspan." The relationship between biomarkers (epigenetic clocks, telomere length, NAD+ levels, etc.) and clinical outcomes is partially understood and still evolving.

Optimistic timeline framing. The geroscience field is making real progress, but human RCT data for healthspan-extending interventions is sparse. Confidence in any specific intervention is typically lower than the marketing implies.

What "longevity" should mean in good consumer content

Used carefully, longevity-themed consumer content can describe:

• The state of the geroscience research field
• Population-level differences in healthspan and lifespan
• The mechanisms researchers propose for age-related disease
• The trial pipeline and where it has reported results
• The gap between marketing claims and clinical evidence
• The limits of current measurement

Used carelessly, the term degenerates into marketing for anything anyone wants to sell. Proco's editorial position is to treat the term precisely, distinguish healthspan from lifespan in every relevant context, and resist the temptation to claim that anything specifically extends either.

Related Proco pages

• How to read a clinical trial
• The wellness economy in 2026
• How supplements are regulated: EU vs US vs UK
• The state of consumer health AI in 2026 (coming soon)

Sources

Proco provides educational, research-based information. This page describes how the longevity research field defines and measures its outcomes. It does not recommend interventions. Decisions about personal health belong with a qualified healthcare professional.

Schema (for implementation)

{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "Healthspan vs Lifespan: What Longevity Research Actually Measures",
  "description": "Longevity research distinguishes lifespan (total years lived) from healthspan (years lived in good health). This page describes the definitions, measurement, and current state of the field.",
  "datePublished": "2026-06-01",
  "dateModified": "2026-05-31",
  "author": {"@type": "Organization", "name": "Proco"},
  "publisher": {"@type": "Organization", "name": "Proco", "url": "https://procohq.com"},
  "about": {"@type": "Thing", "name": "Healthspan and lifespan in longevity research"}
}